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Crystal Structure of a Squalene Cyclase in Complex
with the Potential Anticholesteremic Drug Ro48-8071
cavity, where it initiates the cyclization by protonating
a terminal double bond [5, 6]. The cavity is connected by
a nonpolar channel to a hydrophobic plateau structure,
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Albert-Ludwigs-Universita¨t which is probably inserted into the nonpolar interior of
the membrane (Figure 2). The channel is constricted byD-79104-Freiburg im Breisgau
Germany residues Phe166, Val174, Phe434, and Cys435
Upon protonation, ring A and probably also ring B are
formed in a concerted process [7]. Rings C and D are
considered to arise from rearrangements of five-mem-Summary
bered rings that were formed by Markovnikov-like ring
closure reactions [8, 9]. After cyclization of ring E, the finalSqualene-hopene cyclase (SHC) catalyzes the conver-
carbocation on C22 is either deprotonated or quenched bysion of squalene into pentacyclic compounds. It is the
a water molecule to yield hopene or diplopterol, respec-prokaryotic counterpart of the eukaryotic oxidosqua-
tively (Figure 1B). The carbocationic intermediates arelene cyclase (OSC) that catalyzes the steroid scaffold
stabilized by cation- interactions with tryptophans andformation. Because of clear sequence homology, SHC
phenylalanines, which provide an electron-rich but alsocan serve as a model for OSC, which is an attractive
non-nucleophilic environment [10].target for anticholesteremic drugs. We have estab-
An elevated cholesterol level in the plasma is a majorlished the crystal structure of SHC complexed with
risk factor in the development of atherosclerotic vascu-Ro48-8071, a potent inhibitor of OSC and therefore of
lar diseases. Currently, cholesterol biosynthesis is re-cholesterol biosynthesis. Ro48-8071 is bound in the
duced by inhibiting the rate-limiting enzyme 3-hydroxy-active-center cavity of SHC and extends into the chan-
3-methylglutaryl coenzyme A (HMG-CoA) reductase bynel that connects the cavity with the membrane. The
so-called statins. These, however, can cause adversebinding site of Ro48-8071 is largely identical with the
effects due possibly to the suppression of ubiquinone,expected site of squalene; it differs from a previous
dolichol, and isopentenyl-tRNA farther along the me-model based on photoaffinity labeling. The knowledge
valonate pathway [11]. Moreover, HMG-CoA reductaseof the inhibitor binding mode in SHC is likely to help
biosynthesis is upregulated upon inhibition [12]. OSC isdevelop more potent inhibitors for OSC.
an attractive target for novel anticholesteremic drugs
because it acts downstream from important branching
Introduction points in the cholesterol pathway and because the inhi-
bition of OSC happens to avoid accumulation of steroi-
Oxidosqualene cyclase (OSC) catalyzes the key step in dal intermediates. OSC inhibition raises the concentra-
the conversion of the linear triterpene (3S)-2,3-oxidos- tions of 2,3;22,23-dioxidosqualene and oxysterols that
qualene into fused-ring compounds such as cycloar- down-regulate the HMG-CoA reductase activity via a
tenol in plants or lanosterol in mammals and fungi [1, 2]. negative-feedback loop.
Lanosterol is the precursor of cholesterol and numerous Potent, orally active inhibitors of human hepatic OSC
steroidal hormones. The prokaryotic counterpart of this are Ro48-8071 containing a benzophenone (BP) moiety
enzyme is squalene-hopene cyclase (SHC), which trans- (Figure 1C) [13], BIBX-79 [14], BIBB-515 [15], and qui-
forms squalene into the five-membered ring systems nuclidine inhibitors [16]. Ro48-8071 inhibited OSC in vitro
hopene and diplopterol (Figure 1). These compounds with an IC50 of 6.5 nM for human liver microsomes [13]are processed to a great variety of hopanoids stabilizing and 40 nM for homogenous rat liver OSC [17]. Moreover,
the bacterial membrane [3]. Both OSC and SHC are Ro48-8071 blocked cholesterol biosynthesis in vivo by
membrane proteins, as demonstrated by solubilization selective inhibition of OSC in HepG2 cells and, when
experiments with detergents. The sequence identity administered orally, in Syrian hamsters, squirrel mon-
within the individual prokaryotic and eukaryotic families keys, and Go¨ttingen minipigs [13]. Furthermore, Ro48-
is always above 31%. The sequence identity between 8071 was shown to inhibit the SHC from A. acidocalda-
these two families ranges from 16% to 21%. The se- rius [17, 18]. Here we report at 2.8 A˚ resolution the crystal
quences of human OSC and that of the only structurally structure of the SHC:Ro48-8071 complex, showing a
known SHC from A. acidocaldarius [4] contain 20% iden- binding mode of Ro48-8071 that agrees with the ex-
tical residues at important positions and are therefore pected binding mode of squalene but differs substan-
clearly homologous. tially from a previous model based on photolabeling [18].
The structure of SHC was solved in three crystal forms
[4, 5] showing a dimeric monotopic integral membrane
protein consisting of two / barrel domains. A large Results and Discussion
central cavity is enclosed by loops and a short five-
stranded  sheet linking the barrel domains. Asp376 of Kinetic Characterization
the conserved motif DXDD is located at the “top” of the The inhibition of the SHC from A. acidocaldarius by
Ro48-8071 showed an IC50 value of 9.0 nM [17]. More-
over, the inhibition pattern suggested noncompetitive1Correspondence: schulz@bio.chemie.uni-freiburg.de
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action of the compound, implying that the inhibitor site related by a 180 rotation of the fluorophenyl group. The
conformation sketched in Figure 1C was the major one,differs from that of the substrate squalene [18]. We re-
with 62% occupancy. In both conformations fluorinepeated the kinetic measurements with an alternative
makes comfortable contacts to the environment, namelyassay, utilizing a gas chromatographic analysis of sub-
to Met42-C (4.3 A˚), Pro263-C (3.5 A˚), and Phe605-Cstrate and product concentrations. For determining the
(3.6 A˚) in the major conformation as well as to Trp169-IC50 value, the reaction rates were measured at a con-
C (3.1 A˚), Trp169-C1 (3.2 A˚), and Phe601-C (3.4 A˚) instant squalene concentration of 20 	M and Ro48-8071
the other. Accordingly, the affinity of the inhibitor mayconcentrations ranging between 5 nM and 100 	M. The
increase upon the introduction of a second fluoro sub-resulting plot showed an IC50 value of 61 nM (Figure 3A).
stituent in meta position to the first one.The kinetic properties of SHC were determined with
Ro48-8071 was bound in the large active-center cavitysubstrate concentrations between 10 	M and 100 	M
of all three NCS-related protomers in the crystal. It ex-and Ro48-8071 concentrations up to 60 nM. The re-
tended from the initial protonation site at the “top” of thesulting double-reciprocal plot showed apparent kinetic
cavity down into the putative substrate uptake channelconstants of kcat 
 72 min1 and KM 
 38 	M and a
(Figures 2 and 4) occupying 445 A˚3 of the 1070 A˚3 cavitymixed noncompetitive inhibition pattern (Figure 3B). The
volume. Several water molecules known from the high-observed IC50, kcat, and KM values differ appreciably from
resolution structure [5] had been displaced. The NCS-previous reports (IC50 
 9 nM, kcat 
 2.4 min1, KM 

related protomers showed an rmsd-C smaller than1.6 	M in [17]; kcat 
 289 min1, KM 
 16.7 	M in [19]).
0.2 A˚. Moreover, the SHC structure remained unchangedThese variations are most probably caused by different
upon Ro48-8071 binding (rmsd-C 0.27 A˚), indicatingassay methods and different detergents.
that the flexible inhibitor had adapted itself to the rigid
active center.
Structure of the SHC:Ro48-8071 Complex The occupation of the putative squalene site by Ro48-
The rather nonpolar Ro48-8071 was bound to the dis- 8071 seems to contradict the observed mixed noncom-
solved enzyme and subsequently cocrystallized. An ini- petitive inhibition pattern. It is likely that this discrepancy
tial (Fobs  Fcalc)-electron density map was calculated results from the biphasic state needed for the enzyme
from a 2.8 A˚ data set collected from three crystals (Table activity measurements because the assay requires a
1). It allowed the unambiguous identification of the inhib- detergent for solubilizing the enzyme and the substrate.
itor binding site (Figures 2, 4, and 5). Besides the allyl SHC, squalene, and at least part of Ro48-8071 are lo-
group, Ro48-8071 was completely outlined at the 3  cated in mixed detergent micelles so that substrate and
contour level, and the bromo substituent reached a peak inhibitor availability may influence the kinetic behavior of
height of 11 . the system. As a consequence, the common Michaelis-
Menten interpretation [20] is not applicable.The refinement revealed two inhibitor conformations
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Table 1. Data Collection and Refinement Statistics
Space group P3221
Cell constants (A˚) a 
 b 
 140.9, c 
 244.0
Resolution limit (A˚) 2.8
Total number of reflections 156593
Number of unique reflections 54290
Rsyma,b (%) 10.0 (20.6)
Completenessa (%) 79 (48)
I/1a 5.0 (3.4)
Resolution range of refinementc (A˚) 25–2.8
Number of protein atoms 14980
Number of water molecules 255
Rcrystb (%) 20.3
Rfreeb (%) 25.9
Average B factor, buried atoms (A˚2) 35
Average B factor of Ro48-8071 (A˚2) 38
a Parentheses refer to the last shells. All data were used without 
cutoff. The threefold NCS averaging may compensate for the low
completeness.
b Rsym 
 hkl,i|Ihkl,i  Ihkl|/hkl,iIhkl,i; Rcryst 
 hkl||Fobs|  k|Fcalc||/hkl|Fobs|;
Rfree 
 Rcryst for a 3.7% test set not used in the refinement.
c The rmsd bond lengths and angles were 0.010 A˚ and 1.46, respec-
tively. A Ramachandran plot showed 87% of the non-glycine and
non-proline residues in the most favored regions and none in the
disallowed regions [35]. A cis-peptide between Val491 and Asn492
[5] was also present in the complex structure.
under enzyme assay and crystallization conditions (pre-
dicted pKa, 10.2). It interacts with the amino acid resi-Figure 2. Ribbon Model of SHC with a Space-Filling Model of Bound
dues that initiate the cyclization and stabilize the earlyRo48-8071
high-energy intermediates (Figure 6). In detail, the pro-Fluorine is green; bromine is purple. The inner and outer helices are
tonated amino nitrogen is at a 4.6 A˚ distance to Asp376-yellow and red, respectively. The channel constriction residues, the
putative catalytic acid Asp376 [4], and the photolabeled Ala44 [18] O2 of the conserved sequence motif DXDD and at a
are shown as light-green ball-and-stick models. The nonpolar pla- 2.9 A˚ distance to a water molecule known from the high-
teau, assumed to plunge into the nonpolar membrane interior, con- resolution SHC structure [5]. Moreover, it forms an ion
sists of helices 8 and 310 as well as loops L6, L8, and L15. It pair with the DXDD motif couple Asp374/Asp377, whichharbors the channel entrance (E), indicated by a dotted line.
probably carries one negative charge [5], and it receives
dielectric stabilization from Tyr420 and Tyr609 at hy-
droxyl oxygen distances of 5.1 and 4.6 A˚, respectively.Interactions of SHC with Ro48-8071
The alkyl spacer between the benzophenone moiety and In addition, the protonated amino group is stabilized by
cation- interactions with Trp489, Trp312, and Phe365the allyl-amino group (Figure 1C) adopts a rather elon-
gated conformation with an N to (ether-)O distance of at distances between 4.8 and 5.6 A˚ to the ring centroids.
In agreement with ab initio molecular orbital calculations7.5 A˚ (Figure 5). The allyl-amino group is protonated
Figure 3. Kinetics of SHC Inhibition by Ro48-8071
(A) Dose-response plot at a squalene concentration of 20 	M.
(B) Double-reciprocal plots for the inhibitor concentrations 0 (squares), 15 (circles), 45 (triangles), and 60 nM (diamonds), respectively.
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with tryptophans and phenylalanines and by dipoles of
tyrosines. A carboxyl oxygen of the anionic subsite was
found at a distance of 4.4 A˚ to the inhibitor nitrogen;
this distance matches that observed in the Ro48-8071
complex.
The BP moiety of Ro48-8071 extends into the putative
substrate uptake channel (Figures 4 and 5). Phe129 sta-
bilizes the bromophenyl group by an edge-to-face inter-
action. The observed ring centroid distance is 5.5 A˚
and corresponds to the most frequent distance of 5.6 A˚
found for such interactions [24]. The orientation of the
Trp169 edge toward the plane of the bromophenyl group
with a distance of 5.6 A˚ between the ring centroids may
also indicate a CH- interaction, although Trp-Phe pairs
seem to prefer the reverse geometry [25]. The carbonyl
group of the BP moiety lacks a hydrogen bonding part-
ner. This agrees with inhibition studies of OSC in which
the inhibitory potency of compounds containing aryl-X-
aryl groups [16] shows no dependence on the hydrogen
bond acceptor properties of the linker X. In our structure
the carbonyl carbon of BP may be stabilized by the 
Figure 4. Surface Representation of SHC Sliced through the Middle system of Phe605, the centroid of which is located at a
of the Molecule distance of 5.3 A˚. Because aromatic CH- interactions
The surfaces are colored as nonpolar (yellow) and positively (blue) are rather weak [24, 26], we suggest that the decisive
and negatively (red) charged. The large internal cavity is connected contribution to the Ro48-8071 position comes from the
by a nonpolar channel to a hydrophobic surface patch that dips protonated amino group, in agreement with the almost
into the membrane. The channel constriction (C) permits substrate
identical nitrogen position of LDAO (Figure 7).passage because Phe434 and Cys435 are on a mobile loop. Ro48-
8071 (major conformation) occupies the active-center cavity and
the channel up to the constriction. Asp376 and Ala44 are shown as
Comparison with Previous Modelsball-and-stick models.
The benzophenone system of tritiated Ro48-8071 was
used to photolabel rat liver OSC and A. acidocaldarius
SHC [17]. The putative attachment site Ala44 of SHC[21], the ammonium charge is closer to the benzene
than to the pyrrol moieties of both tryptophans. was determined by digestion of labeled protein and sub-
sequent RP-HPLC separation and Edman degradationThe binding mode of Ro48-8071 resembles that of the
detergent N,N-dimethyl-laurylaminoxide (LDAO) found of the resulting peptides [18]. Consequently, Ala44 was
set as a pivotal point in modeling the Ro48-8071:SHCin the first reported crystal structure of SHC [4]. The
protonated amino group in conjunction with the hydro- complex. Two inhibitor binding modes, both with the
carbonyl oxygen of the BP moiety forming a hydrogengen bonded water molecule is positioned at almost the
same site and in almost the same orientation as the bond with the main chain amide at position 45, were
proposed. Both models are distinctly different from theaminoxide (Figure 7). Therefore, an optimization of
Ro48-8071 directed at mimicking this water position observed binding mode in the crystal, although the in-
hibitor binding procedures were performed under similarshould improve binding. Similar protein-inhibitor inter-
actions have been observed in complexes of acetylcho- conditions. In our structure the carbonyl carbon of Ro48-
8071 and Ala44-C are 14 A˚ apart (Figure 5), which ex-linesterase with inhibitors containing quaternary ammo-
nium groups [22, 23] (Figure 6). In the so-called “anionic” ceeds by far the maximum distance for the photoin-
duced labeling reaction of 3.1 A˚ [27]. Moreover, placingand “peripheral anionic” subsites of this enzyme, the
positive charge is stabilized by cation- interactions Ro48-8071 close to Ala44 requires substantial changes
Figure 5. Stereo View of the Binding Mode
of Ro48-8071 at SHC
The inhibitor is outlined by an (Fobs  Fcalc)
omit map of the final model at a contour level
of 5 . Residues interacting with the inhibitor
and residues of the helix containing Ala44 are
shown. The four channel constriction resi-
dues are in green. The dotted line indicates
the 14 A˚ distance between the carbonyl group
of the inhibitor and the photoaffinity-labeled
Ala44.
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Figure 6. Comparison of Inhibitor Binding in
SHC and Acetylcholine Esterase
Stereo view showing the stabilization of the
protonated allyl-amino group of Ro48-8071
in SHC (top) and of the quaternary allyl-
ammonium group of Bw284C51 at the anionic
subsite of acetylcholine esterase (bottom,
PDB code 1E3Q). Inhibitor truncations are in-
dicated by large dots. Dotted lines mark cat-
ion- interactions (green), hydrogen bonds,
or ion-pair (red) and dipole interactions (blue).
in a rigid part of the protein structure because Ala44 is which is slightly larger than the 11.2 A˚ distance between
the initial and final carbocations in hopene (Figures 1Bon that side of an  helix that is turned away from the
active-center cavity and therefore not accessible (Fig- and 7). The hexacarbon spacer of Ro48-8071 adopts a
quite elongated conformation so that the C
O group isures 4 and 5). Therefore, we conclude that the binding
modes derived from photolabeling can be quite different positioned in an electron-rich environment in the lower
part of the active-center cavity. In comparison with thefrom those in the low-energy crystal structures, possibly
because the photolabel may trap the protein in an ener- hopene model [5], however, the carbonyl carbon is sepa-
rated by 2.5 A˚ from the final carbocation position (Fig-getically elevated conformation.
ures 1B and 7). On the other hand, it should be noted
that during the cyclization process the hopene scaffoldComparison with Putative Product Binding
Inhibition studies with OSC and compounds similar to may be shifted along the main axis of the cavity so that
the final carbocation position may move farther awayRo48-8071 demonstrated that the distance between the
amine nitrogen and the carbonyl carbon influences the from the initiation site.
inhibitory potency [28]. The lowest IC50 values were ob-
served at 10.7 A˚, which is approximately the expected Significance
distance between the epoxide oxygen and the carbocat-
ion position of the protosteryl cation. The respective Eukaryotic 2,3-oxidosqualene cyclase (OSC) catalyzes
a key step in cholesterol biosynthesis. Squalene-N-to-C
O distance for bound Ro48-8071 is 12.5 A˚,
Figure 7. Superposition of Ro48-8071, a
Modeled Hopene Molecule, and the Deter-
gent LDAO as Bound to SHC
For clarity, the orientation is rotated by 180
around a vertical axis with respect to the
usual view (Figure 5). Hopene [5] is in yellow;
LDAO [4] is in light blue. The conformations
of the depicted side chains are nearly identi-




X-Ray Diffraction Analysishopene cyclase (SHC) is the prokaryotic homolog of
Data to 2.8 A˚ resolution were collected at room temperature fromOSC, so that the crystal structure of SHC:inhibitor
three isomorphous crystals by the use of an area detector (modelcomplexes elucidates the interactions determining in-
X-1000, Nicolet-Bruker) with Cu K radiation (model RU200B, Rigaku).hibitor efficiency. The structure of SHC ligated with Despite an intensive search, we failed to establish a cryo protocol
Ro48-8071, the most potent inhibitor known for this that sufficiently preserved the diffraction quality of the crystals at
100 K. Data were processed with programs XDS [30], SCALA, andenzyme, was established by X-ray diffraction analysis
TRUNCATE [31]. After rigid body refinement with NCS constraintsof cocrystals. Ro48-8071 and, in particular, its bromo
and the maximum likelihood target in program CNS [32], a (Fobs substituent were unambiguously identified at the puta-
Fcalc) difference electron density map was calculated by using thetive squalene binding site in the active center. Its loca-
SHC structure with water molecules removed as the reference (PDB
tion differs from that of a model based on photoaffinity code 3SQC). Coordinates for an energy-minimized conformation of
labeling. The inhibitor position appears to be dominated the inhibitor were generated with the program SYBYL (Tripos, St.
Louis/USA), and topology and parameter files were generated withby the interactions of its protonated amino group, with
the program XPLO2D [33]. Structural refinement, including all data,the amino acid residues catalyzing the protonation of
bulk solvent correction, and NCS restraints, was performed with thesqualene. Further stabilization is achieved by cation
program CNS. Manual rebuilding was done in the program O [34].and CH- interactions. The addition of a second fluo-
B factors were refined in groups, with two B factors per amino acid
rine atom and the mimicking of a water molecule hy- (main chain, side chain) and four B factors for the inhibitor molecules
drogen bonded to the protonated amino group have (amino headgroup, alkyl spacer region, fluorophenyl group, and car-
bonyl/bromophenyl group). After two alternate conformations of thebeen proposed as possibilities for future inhibitor de-
inhibitor appeared, these were refined with different occupanciesvelopment. The apparent discrepancy between the ki-
because equal occupancies led to unrealistically low B factors for onenetic mixed noncompetitive inhibition pattern and the
of the conformers. The model quality was assessed with the programsoccupation of the squalene binding site is spurious
PROCHECK [35] and WHATCHECK [36]. Molecular volumes were cal-
because the required biphasic system of the assay culated with VOIDOO [37] and GRASP [38]. Figures were produced
probably fails to obey Michaelis-Menten kinetics. with the programs MOLSCRIPT [39] and Raster3D [40].
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